Photo from wikipedia
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial… Click to show full abstract
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.
Keywords:
treatment;
treatment resistant;
esketamine;
nasal spray
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!